Key result
Reduced-dose apixaban was used to treat left ventricular thrombus in two older patients without any thrombus- or treatment-related complications.
Why the study?
Warfarin has historically been standard care for left ventricular thrombus, and DOACs are not FDA-indicated despite growing use and recognition as a reasonable alternative.
Is reduced-dose apixaban safe and effective for the treatment of left ventricular thrombus?
Case Report (n=2)
Is reduced-dose apixaban safe and effective for the treatment of left ventricular thrombus?
Reduced-dose apixaban (2.5 mg twice daily) may be a safe and effective alternative to warfarin for the treatment of left ventricular thrombus.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for reduced-dose apixaban in LV thrombus among older patients; larger prospective trials needed before practice change.
According to the American College of Cardiology and the American Heart Association, warfarin has historically been the standard of care anticoagulant for the treatment of left ventricular thrombus. The use of direct oral anticoagulants (DOACs) has become more prevalent, as they require less frequent laboratory monitoring, offer fixed-dose regimens, are associated with fewer drug-drug and drug-food interactions, and provide more favorable safety profiles when compared to warfarin. However, DOACs are not currently FDA-indicated in the treatment of left ventricular (LV) thrombus. Numerous recent studies have reported and evaluated the use of DOACs for treatment of LV thrombus. Recently, a prospective, open-label, multicenter study evaluated warfarin compared to DOACs for LV thrombus treatment. The AHA recently published a scientific statement regarding the management of patients at risk for and with left ventricular thrombus, which included DOACs as a reasonable alternative to warfarin. This report describes two patients treated with DOACs following LV thrombus diagnosis. The first case is a 71-year-old male admitted for cerebrovascular accident and non-ST-elevation myocardial infarction complicated by a LV thrombus. The second case is an 83-year-old female admitted for acute myocardial infarction complicated with an LV thrombus. Both patients were prescribed apixaban 2.5 mg twice daily. Neither patient has experienced LV thrombus or DOAC treatment related complications. This case series serves as evidence for reduced-dose DOACs as an alternative to warfarin in the treatment of LV thrombus.
No takes yet. Share an insight, caveat, or question.
Bundrick et al. (2022) conducted a case report in Left ventricular thrombus (n=2). Apixaban was evaluated on LV thrombus or DOAC treatment related complications. Reduced-dose apixaban was used to treat left ventricular thrombus in two older patients without any thrombus- or treatment-related complications.
Synapse has enriched 10 related papers. Consider them for comparative context: